Search
Benzyl benzoate
go.drugbank.com/drugs/DB00676ApprovedBenzyl benzoate is one of the older preparations used to treat scabies. Scabies is a skin infection caused by the mite sarcoptes scabiei. … It is characterised by severe itching (particularly at night), red spots, and may lead to a secondary infection. Benzyl benzoate is lethal to this mite and so is useful in the treatment of scabies.
International brands: BE BOTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.
Zinc sulfate
go.drugbank.com/drugs/DB09322ApprovedInvestigationalIt is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mixtures: Clear Eyes Acr By Murine, Neo-vites & Minerals TabProducts: ZINC GO FORTEChloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration, similar to the one observed with [lidocaine]. … Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential.
Favipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigational[A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedRecommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory … Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.
Adalimumab
go.drugbank.com/drugs/DB00051ApprovedInvestigational[A39983] Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.[L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. … A high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), a biosimilar to Humira®, was approved by the FDA in May 2024 for the treatment of multiple chronic inflammatory diseases.
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.
Categories: Antiinflammatory and Antirheumatic Products, Non-SteroidsAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawn[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113] … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Moxisylyte
go.drugbank.com/drugs/DB09205Approved[T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.